Dynamic quotes: Off
|
ETFs with AFFY as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 2.9% | SPDR Series Trust SPDR S&P Biotech ETF (XBI) | +5.97 (6.97%) |
| 2.28% | N/A (SHVY) | +0.96 (2.34%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are a biopharmaceutical company committed to discovering, developing and delivering innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses. In March 2012, the U.S. Food and Drug Administration, or FDA, approved our first product, OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate production of red blood cells. Our product is the only once-monthly ESA that has been available to the adult dialysis patient population in the U.S. In 2012, we co-commercialized OMONTYS in the U.S. with our collaboration partner, Takeda Pharmaceutical Company Limited, or Takeda, the largest pharmaceutical company in Japan. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-1.33 |
| Quarterly EPS Est: | -0.75 |
| PEG Ratio: | -.03 |
|
Mean Recommendation: View Summary / View All |
3 |
Data is provided by Zacks Investment Research

